Etanercept decreases the innate immune wounding response in psoriasis

Experimental Dermatology

Volumn 22, Issue 9, 2013, Pages 599-608

  Hata, Tissa R ^a   Afshar, Maryam ^a   Miller, Jeremiah ^a   Two, Aimee M ^a   Kotol, Paul ^a,b   Jackson, Michelle ^a   Alexandrescu, Doru T ^a   Kabigting, Filamer ^a   Gerber, Monika ^a   Lai, Yuping ^c   Gallo, Richard L ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^c EAST CHINA NORMAL UNIVERSITY   (China)

Author keywords

Cathelicidin; Etanercept; Psoriasis; TLR 9

Indexed keywords

CATHELICIDIN; ETANERCEPT; TOLL LIKE RECEPTOR 9;

CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; INNATE IMMUNITY; LETTER; PROTEIN EXPRESSION; PSORIASIS; TREATMENT RESPONSE; WOUND HEALING;

EID: 84882276988     PISSN: 09066705     EISSN: 16000625     Source Type: Journal    
DOI: 10.1111/exd.12167     Document Type: Letter

References (14)

1. Ong P Y, Ohtake T, Brandt C et al. N Engl J Med 2002: 347: 1151-1160.
2. Nomura I, Goleva E, Howell M D et al. J Immunol 2003: 171: 3262-3269.
3. Howell M D, Novak N, Bieber T et al. J Invest Dermatol 2005: 125: 738-745.
4. Yamasaki K, Di Nardo A, Bardan A et al. Nat Med 2007: 13: 975-980.
5. Schauber J, Dorschner R A, Coda A B et al. J Clin Invest 2007: 117: 803-811.
6. Lande R, Gregorio J, Facchinetti V et al. Nature 2007: 449: 564-569.
7. Dombrowski Y, Schauber J. Exp Dermatol 2012: 21: 327-330.
8. Zaba L C, Cardinale I, Gilleaudeau P et al. J Exp Med 2007: 204: 3183-3194.
9. Guttman-Yassky E, Nograles K E, Krueger J G. J Allergy Clin Immunol 2011: 127: 1420-1432.
10. Kim B J, Rho Y K, Lee H I et al. Clin Dev Immunol 2009: 2009: 645898.
11. Peric M, Koglin S, Kim S et al. J Immunol 2008: 181: 8504-8512.
12. Bose F, Raeli L, Garutti C et al. Clin Immunol 2011: 139: 164-176.
13. Morizane S, Yamasaki K, Muhleisen B et al. J Invest Dermatol 2012: 132: 135-143.
14. Gambichler T, Kobus S, Kobus A et al. Regul Pept 2011: 167: 163-166.